Skip to main content

Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer.

Publication ,  Journal Article
Wan, X; Huang, J; Huang, L; Wang, Y; Fu, Y; Jin, X; Huang, Z; Xiong, J
Published in: Discov Oncol
May 15, 2024

BACKGROUND: Studies evaluating the effectiveness of immune checkpoint inhibitors (ICI) for endometrial cancer (EC) are limited. This study aimed to assess the efficacy of PD-1/PD-L1 inhibitors as monotherapy for EC by conducting a meta-analysis. The predictive significance of MMR status, a biomarker for ICI response, also required further investigation. METHODS: A systematic literature search was conducted in English databases until September 2023. The analysis included objective response rate (ORR), disease control rate (DCR), adverse events (AEs), and odds ratios (OR), along with their corresponding 95% confidence intervals (CI). RESULTS: There were twelve trials totaling 685 individuals. PD-1/PD-L1 inhibitor monotherapy resulted in an ORR for 34% (95% CI = 24-44%) of the pooled EC patients. Subgroup analysis revealed a significantly higher ORR in dMMR EC (45%) compared to pMMR EC (8%), with an OR of 6.36 (95% CI = 3.64-11.13). The overall DCR was 42%, with dMMR EC at 51% and pMMR EC at 30% (OR = 2.61, 95% CI = 1.69-4.05). Grade three or higher adverse events (AEs) occurred in 15% of cases (95% CI = 9-24%) of the pooled incidence of AEs, which was 68% (95% CI = 65-72%). CONCLUSIONS: This meta-analysis provides significant evidence for the effectiveness of PD-1/PD-L1 inhibitors as monotherapy for EC. Notably, dMMR EC patients demonstrated superior treatment efficacy with PD-1/PD-L1 inhibitor immunotherapy. Further research is required to explore subclassifications of EC based on dMMR molecular subtypes, enabling improved treatment strategies and outcomes for EC patients.

Duke Scholars

Published In

Discov Oncol

DOI

EISSN

2730-6011

Publication Date

May 15, 2024

Volume

15

Issue

1

Start / End Page

168

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wan, X., Huang, J., Huang, L., Wang, Y., Fu, Y., Jin, X., … Xiong, J. (2024). Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer. Discov Oncol, 15(1), 168. https://doi.org/10.1007/s12672-024-01033-w
Wan, Xiaoyan, Jiezheng Huang, Liu Huang, Yibin Wang, Yiyuan Fu, Xiaolong Jin, Zheng Huang, and Jian Xiong. “Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer.Discov Oncol 15, no. 1 (May 15, 2024): 168. https://doi.org/10.1007/s12672-024-01033-w.
Wan X, Huang J, Huang L, Wang Y, Fu Y, Jin X, et al. Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer. Discov Oncol. 2024 May 15;15(1):168.
Wan, Xiaoyan, et al. “Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer.Discov Oncol, vol. 15, no. 1, May 2024, p. 168. Pubmed, doi:10.1007/s12672-024-01033-w.
Wan X, Huang J, Huang L, Wang Y, Fu Y, Jin X, Huang Z, Xiong J. Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer. Discov Oncol. 2024 May 15;15(1):168.

Published In

Discov Oncol

DOI

EISSN

2730-6011

Publication Date

May 15, 2024

Volume

15

Issue

1

Start / End Page

168

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis